Sign in
Active, not recruitingNo phase

Vector Velocity Imaging in AAA Patients

Key facts

Who runs it
St. Olavs Hospital
Where
Norway1 site in 1 countryChoose a country to see its sites
Trial code
Status
Active, not recruiting
People taking part
14 people enrolled
Started
1 Apr 2023
Expected to end
31 Dec 2026
Type of study
Observational, 2 groups
Treatments tested
  • Vector flow imaging measurement
Record updated
21 July 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (12)Hide the full registry criteria

Who can take part

  • Diagnosed with AAA
  • AAA diameter below treatment threshold of 5.5 cm

Who cannot take part

  • Hypersensitivity to the active substance(s) or any of the excipients in Sonovue
  • Right-to-left cardiac shunt
  • Severe pulmonary hypertension (pulmonary artery pressure > 90mmHg)
  • Uncontrolled systemic hypertension
  • Severe pulmonary disease (e.g. COPD GOLD 3 or 4, adult respiratory distress syndrome)
  • Clinically unstable cardiac disease (recent, < 3 months, or ongoing myocardial infarction, unstable angina at rest, recent percutaneous coronary intervention, clinically worsening cardiac symptoms, severe cardiac arrhythmia's, endocarditis, etc.)
  • End-stage liver disease
  • Loss of renal function (GFR < 31 ml/min), end-stage renal disease
  • Prosthetic valves
  • Sepsis

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The goal of this observational study is to perform an in vivo feasibility study using real time (3D) ultrasound based vector flow imaging in 10 AAA patients (5 with intraluminal thrombus and 5 without intraluminal thrombus). Furthermore, the investigators will investigate the added value of contrast microbubbles in these high framerate, plane wave ultrasound measurements.

Read full original descriptionShow less

Included patients will undergo ultrasound scanning of their AAA, using multiple ultrasound sequences. Sequences will be tested with and without the addition of ultrasound contrast microbubbles.

The 2 groups in the trial

  • AAA patients, without intraluminal thrombus

    patients diagnosed with an abdominal aneurysm, with a diameter below the treatment threshold of 5.5 cm and without intraluminal thrombus.

    Treatment: Vector flow imaging measurement

  • AAA patients, with intraluminal thrombus

    patients diagnosed with an abdominal aneurysm, with a diameter below the treatment threshold of 5.5 cm and with intraluminal thrombus.

    Treatment: Vector flow imaging measurement

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Thrombus Formation Prediction in Abdominal Aneurysms Using Vector Flow Imaging
Record updated
21 July 2026